Apellis Pharmaceuticals Inc (APLS.OQ)
APLS.OQ on NASDAQ Stock Exchange Global Select Market
18.69USD
14 Dec 2018
18.69USD
14 Dec 2018
Change (% chg)
$-0.02 (-0.11%)
$-0.02 (-0.11%)
Prev Close
$18.71
$18.71
Open
$18.62
$18.62
Day's High
$18.96
$18.96
Day's Low
$18.33
$18.33
Volume
120,111
120,111
Avg. Vol
102,892
102,892
52-wk High
$31.69
$31.69
52-wk Low
$11.45
$11.45
Revenue & Earnings Per Share
| Revenue* | Earnings Per Share** | ||
|---|---|---|---|
| FY 2018 | Sep '18 | 0.00 | -0.640 |
| Jun '18 | 0.00 | -0.609 | |
| Mar '18 | 0.00 | -0.432 | |
| FY 2017 | Dec '17 | 0.00 | -0.371 |
| Sep '17 | 0.00 | -0.235 | |
| Jun '17 | 0.00 | -0.246 | |
| Mar '17 | 0.00 | -0.184 | |
| FY 2016 | Dec '16 | 0.00 | -0.134 |
| Sep '16 | 0.00 | -0.146 | |
| Jun '16 |
*Note: Units in Millions ofU.S. Dollars
**Note: Units in U.S. Dollars
Consensus Estimates Analysis
| # of Estimates | Mean | High | Low | 1 Year Ago | |
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Dec-18 | 3 | 0.00 | 0.00 | 0.00 | -- |
| Quarter Ending Mar-19 | 2 | 0.00 | 0.00 | 0.00 | -- |
| Year Ending Dec-18 | 3 | 0.00 | 0.00 | 0.00 | 0.00 |
| Year Ending Dec-19 | 3 | 0.00 | 0.00 | 0.00 | 0.00 |
| Earnings (per share) | |||||
| Quarter Ending Dec-18 | 4 | -0.70 | -0.65 | -0.75 | -0.38 |
| Quarter Ending Mar-19 | 4 | -0.73 | -0.70 | -0.77 | -- |
| Year Ending Dec-18 | 4 | -2.41 | -2.35 | -2.45 | -1.36 |
| Year Ending Dec-19 | 4 | -3.04 | -2.85 | -3.24 | -1.70 |
Sales and Profit Figures in US Dollar (USD);
Valuation Ratios
| Company | industry | sector | ||
|---|---|---|---|---|
| P/E Ratio (TTM) | -- | 31.13 | 34.39 | |
| P/E High - Last 5 Yrs. | -- | 40.59 | 46.24 | |
| P/E Low - Last 5 Yrs. | -- | 23.99 | 24.59 | |
| Beta | -- | 0.91 | 0.91 | |
| Price to Sales (TTM) | -- | 4.00 | 6.22 | |
| Price to Book (MRQ) | -- | 5.02 | 5.20 | |
| Price to Tangible Book (MRQ) | -- | 5.76 | 6.74 | |
| Price to Cash Flow (TTM) | -- | 23.20 | 24.17 | |
| % Owned Institutions | -- | 0.95 | 1.78 | |
Dividends
| Company | industry | sector | ||
|---|---|---|---|---|
| Dividend Yield | -- | 1.55 | 1.44 | |
| Dividend Yield - 5 Year Avg | -- | 1.56 | 1.46 | |
| Dividend 5 Year Growth Rate | -- | 4.21 | 4.94 | |
| Payout Ratio(TTM) | -- | 45.68 | 42.49 | |
Growth Rates
| Company | industry | sector | ||
|---|---|---|---|---|
| Sales (MRQ) vs Qtr. 1 Yr. Ago | -- | 2.33 | 8.17 | |
| Sales (TTM) vs TTM 1 Yr. Ago | -- | 4.80 | 6.50 | |
| Sales - 5 Yr. Growth Rate | -- | 10.00 | 10.44 | |
| EPS (MRQ) vs Qtr. 1 Yr. Ago | -- | 17.26 | 23.09 | |
| EPS (TTM) vs TTM 1 Yr. Ago | -- | -- | -- | |
| EPS - 5 Yr. Growth Rate | -- | 9.88 | 10.49 | |
| Capital Spending - 5 Yr. Growth Rate | -- | 15.23 | 14.59 | |
Financial Strength
| Company | industry | sector | |
|---|---|---|---|
| Quick Ratio (MRQ) | -- | 2.20 | 2.28 |
| Current Ratio (MRQ) | -- | 3.02 | 3.10 |
| LT Debt to Equity (MRQ) | -- | 8.89 | 11.49 |
| Total Debt to Equity (MRQ) | -- | 12.69 | 16.03 |
| Interest Coverage (TTM) | -- | 35.18 | 30.57 |
Profitability Ratios
| Company | industry | sector | ||
|---|---|---|---|---|
| Gross Margin (TTM) | -- | 54.41 | 54.44 | |
| Gross Margin - 5 Yr. Avg. | -- | 51.86 | 52.36 | |
| EBITD Margin (TTM) | -- | -- | -- | |
| EBITD - 5 Yr. Avg | -- | 18.41 | 13.16 | |
| Operating Margin (TTM) | -- | 14.42 | 6.07 | |
| Operating Margin - 5 Yr. Avg. | -- | 14.55 | 8.47 | |
| Pre-Tax Margin (TTM) | -- | 14.96 | 7.02 | |
| Pre-Tax Margin - 5 Yr. Avg. | -- | 14.97 | 8.71 | |
| Net Profit Margin (TTM) | -- | 11.16 | 3.12 | |
| Net Profit Margin - 5 Yr. Avg. | -- | 11.23 | 4.91 | |
| Effective Tax Rate (TTM) | -- | 23.45 | 23.26 | |
| Effective Tax Rate - 5 Yr. Avg. | -- | 23.65 | 23.83 | |
Efficiency
| Company | industry | sector | ||
|---|---|---|---|---|
| Revenue/Employee (TTM) | -- | 997,011,333 | 873,051,409 | |
| Net Income/Employee (TTM) | -- | 118,232,370 | 103,483,755 | |
| Receivable Turnover (TTM) | -- | 5.82 | 5.80 | |
| Inventory Turnover (TTM) | -- | 2.68 | 3.56 | |
| Asset Turnover (TTM) | -- | 0.99 | 0.95 | |
Management Effectiveness
| Company | industry | sector | ||
|---|---|---|---|---|
| Return on Assets (TTM) | -- | 11.98 | 11.45 | |
| Return on Assets - 5 Yr. Avg. | -- | 13.28 | 12.50 | |
| Return on Investment (TTM) | -- | 15.55 | 14.96 | |
| Return on Investment - 5 Yr. Avg. | -- | 17.28 | 16.23 | |
| Return on Equity (TTM) | -- | 16.92 | 16.52 | |
| Return on Equity - 5 Yr. Avg. | -- | 18.21 | 17.37 | |
Note: Units in Millions of US Dollars
Performance for Apellis Pharmaceuticals Inc
| Period | % Actual |
% vs. S&P 500 |
Rank In Industry |
Industry Rank |
|---|---|---|---|---|
| 4 Week | -- | -- | -- | 20 |
| 13 Week | -- | -- | -- | 34 |
| 26 Week | -- | -- | -- | 28 |
| 52 Week | -- | -- | -- | 12 |
| YTD | -- | -- | -- | 25 |
Note:: Rank is a percentile that ranges from 0 to 99, with 99 = best.
Institutional Holders
| % Shares Owned: | 57.62% |
| # of Holders: | 123 |
| Total Shares Held: | 32,404,681 |
| 3 Mo. Net Change: | -883,582 |
| # New Positions: | 16 |
| # Closed Positions: | 8 |
| # Increased Positions: | 62 |
| # Reduced Positions: | 41 |
| # Net Buyers: | 21 |
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.